Oncovision

What Oncovision does

Oncovision, legally General de Equipment for Medical Imaging, S.A., is a Spanish medical-imaging technology company founded in 2003 and headquartered in Valencia, Spain, that develops dedicated-organ PET systems and intraoperative gamma-imaging devices for oncology and neurology applications. Its product portfolio includes Mammi, a dedicated breast PET scanner; CareMiBrain, a dedicated brain PET system repositioned under the MindView sub-brand for neurological imaging including Alzheimer's and dementia; Sentinella, an intraoperative gamma camera for surgical oncology; and Wprobe, a wireless gamma probe for image-guided surgery. The company combines proprietary detector and reconstruction technology with EU- and Spanish-funded R&D programs such as HEIMDALL and PHOENIX, and runs clinical-validation studies including a 300-patient international multicenter trial for CareMiBrain.

Oncovision generates revenue primarily through capital-equipment sales of its imaging systems to hospitals and surgical centers, supplemented by service and consumables tied to installed gamma-probe procedures. It commercializes through a mix of direct sales and distributor agreements across 30+ markets, operates a U.S. subsidiary in Boston, and in 2025 added an exclusive U.S. distribution partnership with Catalyst MedTech for CareMiBrain, while integrating third-party quantification platforms such as Syntermed NeuroQ4 into its neurology workflow. The company is private, capitalized by Spanish innovation vehicles Innvierte (CDTI) and ACE 53, holds PYME INNOVADORA certification through May 2027, and employs 51-100 people; cumulative disclosed funding across 2012-2024 is approximately $10 million.

The company's strategic posture in 2024-2025 has shifted from a pure oncology-imaging vendor toward a multi-organ, multi-vertical imaging platform spanning breast cancer, neurological disease, and image-guided surgery, with a parallel AI research effort (the SynthCT project using convolutional neural networks to generate synthetic CT from PET data) intended to reduce radiation dose and replace companion CT scans in its imaging workflow.

Name

Oncovision

Legal name

General de Equipment for Medical Imaging, S.A.

Website

https://oncovision.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

51–100 employees

Short description

Oncovision is a Spanish medical-imaging company that develops dedicated breast and brain PET scanners, intraoperative gamma cameras, and wireless gamma probes, selling to hospitals and surgical centers across 30+ markets via direct sales and distributors.

Ownership category

akta.pro rank

Product category

Medical Imaging Equipment

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Nuclear Medicine & Molecular Imaging (SPECT/PET) (HLAHABAE)

akta.pro secondary industry

Mammography & Breast Imaging Systems (HLAHABAF)

Keywords

• Molecular imaging systems
• Breast PET imaging
• Intraoperative gamma cameras
• Dedicated brain PET
• Radioguided surgery devices

Headquarters

HQ city

Mexico City

HQ country

Mexico

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Imaging Hardware Sales: Sale of medical imaging equipment including PET systems, gamma cameras, and gamma probes to hospitals and medical centers for cancer diagnosis and surgical guidance

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Oncovision designs, manufactures, and sells proprietary molecular imaging medical devices for cancer diagnosis and surgical guidance. Its portfolio includes the Mammi dedicated breast PET, the Sentinella intraoperative gamma camera with real-time optical fusion, the Wprobe wireless gamma probe, and the CareMiBrain dedicated brain PET for Alzheimer's and neurological disease diagnosis. Products are sold to hospitals, medical centers, and clinical specialists in more than 30 international markets through direct sales and distributor networks.

Product overview

Oncovision is a medical imaging company offering a portfolio of four core products: Mammi (dedicated breast PET for early breast cancer detection), Sentinella (intraoperative gamma camera with real-time optical fusion for sentinel lymph node surgery), Wprobe (wireless gamma probe for radioguided surgery), and CareMiBrain (dedicated brain PET for Alzheimer's and neurological disease diagnosis). The company also operates a sub-brand, MindView, focused exclusively on international neurological imaging solutions. The products are targeted at surgeons, radiologists, oncologists, and nuclear medicine physicians and are sold across more than 30 markets via direct sales and distributors.

Differentiator

Problem solved

Functional benefit

Brands

• Mindview: Neurological imaging solutions brand launched under Oncovision's growth and internationalization strategy. First product is CareMiBrain, a dedicated brain PET system designed for superior diagnostic precision in neurological imaging.

Products and services

• Mammi Breast PET A dedicated breast PET system offering 1.6 mm spatial resolution for early-stage breast cancer detection, capable of visualizing tumors as small as 2 mm. Uses prone patient positioning with ring geometry for improved lesion detection and patient comfort relative to whole-body PET/CT.
• Sentinella Intraoperative Gamma Camera A 100% portable intraoperative gamma camera that fuses real-time gamma imaging with optical vision for sentinel lymph node detection during surgery. Includes ergonomic arm with laser positioning and integrates with hospital PACS/DICOM systems via the Sentinella Suite software.
• Wprobe Wireless Gamma Probe A wireless gamma probe for sentinel lymph node localization in open and laparoscopic surgeries, offering dual maximum sensitivity (more than 2x competitor probes), Bluetooth connectivity, a 10.1-inch medical-grade tablet, and simultaneous multi-isotope detection (up to three). Available in standard (25 cm) and laparoscopic (51 cm) configurations.
• CareMiBrain Dedicated Brain PET An ultra-high resolution dedicated brain PET system designed for early diagnosis of Alzheimer's disease and other neurological conditions by detecting β-amyloid biomarkers. Funded by the European Union Horizon 2020 program, with seated patient positioning for greater comfort.

Quantifiable outcome

• Visualization of tumors up to 2mm with Mammi breast PET
• +2 more outcomes

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability2 records

Feature4 records

Partnerships

Five partnerships are on record, tiered core.

• Catalyst MedTechcoreChannel Partner/ Reseller/ Distributor · 20 June 2025Catalyst MedTech serves as the exclusive U.S. distributor of CareMiBrain, pairing the ultra-high resolution dedicated brain PET system with Syntermed's NeuroQ4 brain analysis software for epilepsy, oncology, and amyloid analysis applications. The complete neurologic PET solution was showcased at SNMMI 2025.
• Massachusetts General Hospital (USA)coreStrategic or Co-development PartnerParticipating hospital in the international multicenter clinical study for CareMiBrain validation, contributing to the 300-patient study alongside other leading international medical centers
• Hospital Clínico San Carlos (Madrid)coreStrategic or Co-development PartnerLead hospital for the CareMiBrain clinical trial to validate and commercialize the dedicated brain PET system in Europe, conducting pilot study and multicenter international study
• UKT University Hospital Tübingen (Germany)coreStrategic or Co-development PartnerInternational partner in the multicenter clinical study for CareMiBrain validation, contributing to European clinical validation alongside Hospital Clínico San Carlos and Massachusetts General Hospital
• Hospital Universitario y Politécnico La Fe (Valencia)coreStrategic or Co-development PartnerSpanish partner in the international multicenter study for CareMiBrain, contributing to clinical validation alongside other leading hospitals in Europe and the United States

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Canon Medical Systems: Canon Medical Systems (formerly Toshiba Medical) is a major PET/CT and diagnostic imaging manufacturer serving oncology and neurology customers, providing broader whole-body PET competition that benchmarks pricing and performance against Oncovision's dedicated systems.
• GE Healthcare: GE Healthcare is a global leader in molecular imaging with PET, SPECT, and PET/CT offerings, including in oncology and neurology segments where Mammi and CareMiBrain compete for hospital capital budgets.
• Hologic: Hologic is a global leader in women's health imaging, including 3D mammography/tomosynthesis, and competes with Mammi at the hospital breast-imaging budget line. As a broad incumbent, Hologic serves many of the same oncology and breast centers that Oncovision targets.
• Philips: Philips' imaging portfolio includes PET/CT and advanced radiology systems serving oncology and neurology workflows, making it a broad incumbent competitor for Oncovision's installed-base expansion.
• Siemens Healthineers: Siemens Healthineers offers whole-body PET/CT systems and SPECT cameras used for the same clinical applications as Oncovision's gamma cameras and CareMiBrain, including oncology and neurology imaging — providing competitive reference pricing and technology benchmarks.

Direct peers

• Naviscan: Naviscan develops dedicated breast PET (PEM) systems for high-resolution lesion localization, the closest like-for-like competitor to Oncovision's Mammi breast PET — both target the same dedicated-breast-imaging niche with higher resolution than whole-body PET/CT.
• Dilon Diagnostics: Dilon Diagnostics produces molecular breast imaging (MBI) systems (e.g., Dilon 6800) for adjunct breast cancer diagnosis, competing head-to-head with Mammi in the same dedicated-breast-imaging category and overlapping customer base of breast imaging centers.
• IntraMedical Imaging: IntraMedical Imaging manufactures gamma probes used for sentinel lymph node localization in cancer surgery, the closest direct competitor to Oncovision's Wprobe wireless gamma probe in terms of product type and surgical use case.
• SurgicEye: SurgicEye develops intraoperative imaging systems for image-guided surgery, including SPECT-based surgical guidance — directly comparable to Oncovision's Sentinella intraoperative gamma camera for sentinel lymph node detection.

Emerging players

• Lightpoint Medical: Lightpoint Medical develops intraoperative molecular imaging probes and detectors for cancer surgery, overlapping with Sentinella and Wprobe in the radioguided-surgery niche — a smaller emerging alternative focused on miniaturized optical/imaging probes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/oncovision
• Facebookfacebook.com/oncovision
• LinkedInes.linkedin.com/company/oncovision

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds7 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncovision